GMAB - AbbVie-Genmab lymphoma drug shows strong response rate in ongoing trial

2023-12-11 06:20:03 ET

AbbVie ( NYSE: ABBV ) and Genmab ( GMAB ) on Saturday presented latest trial data for their lymphoma drug candidate epcoritamab in patients with difficult-to-treat relapsed/refractory (R/R) follicular lymphoma (FL).

Updated data from Phase 1/2 EPCORE NHL-1 study, presented at the 65th American Society of Hematology congress, showed that patients treated with epcoritamab experienced 82% overall response rates, including 63% complete response rates.

The data included an optimized, step-up dosing schedule showing reduced incidence and severity of cytokine release syndrome, a notable side effect from immune-engaging cancer treatments. No new safety signals were detected.

Epcoritamab is a T-cell engaging bispecific antibody developed with Genmab ( GMAB ) technology. Both AbbVie ( ABBV ) and Genmab ( GMAB ) share commercial rights for the drug in the U.S. and Japan.

The drug received breakthrough therapy designation from the U.S. FDA last month for treatment of relapsed or refractory follicular lymphoma.

More on AbbVie, Genmab, etc.

• AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition
• AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time
• AbbVie: $10 Billion Cancer Deal To Boost Growth
• AbbVie – Cerevel deal reportedly followed unusual options trading
• AbbVie shares set for seventh straight session of gains

For further details see: